In addition to the antigen-specific stimulus delivered by the TCR, T cells under most circumstances require a co-stimulatory signal for complete activation. CD28 can provide this signal, and the importance of CD28-mediated co-stimulation has been well documented both in vitro and in vivo, but the intracellular pathways downstream of CD28 are less well characterized. So far, maximal co-stimulation of IL-2 production has been attributed to tyrosine-based signaling motifs, either including the first cytoplasmic tyrosine residue that binds phosphatidylinositol 3'-kinase (PI3-K), or the third tyrosine residue. Here we describe results of the expression of murine CD28 receptor mutants in a CD28-deficient murine T cell hybridoma, A1.1. We show that in A1.1 cells co-stimulation of IL-2 production is independent of CD28 cytoplasmic tyrosine residues, since a mutant lacking all four cytoplasmic tyrosines is still able to induce a full co-stimulatory response. Using truncation mutants, this activity can be attributed to amino acids 183 to 194, a sequence containing a conserved diproline motif that may recruit SH3 domains of other signaling molecules like Grb2. Thus we have identified a novel pathway for CD28-mediated co-stimulation of IL-2 production that is independent of PI3-K activity and phosphotyrosine-based signaling motifs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/1521-4141(200006)30:6<1632::AID-IMMU1632>3.0.CO;2-Q | DOI Listing |
Adv Sci (Weinh)
December 2024
Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Key Laboratory of Kidney Disease Prevention and Control Technology, National Key Clinical Department of Kidney Diseases, Institute of Nephrology, Zhejiang University, Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, Zhejiang, 310003, P. R. China.
The establishment of a tolerant space to realize the co-stimulation of cytokines and contact-dependent molecules remain challenging in allotransplant. Here, an injectable genetically engineered hydrogel (iGE-Gel) is reported, which developed with a multivalent network of FOXP3 engineered extracellular vesicles (Foe-EVs) through the hydrophobic interaction between stearic acid modified hyaluronic acid (HASA) and the membrane phospholipids of extracellular vesicles (EVs). The iGE-Gel exhibited self-healing properties, injectability and biocompatibility.
View Article and Find Full Text PDFElife
September 2024
Center for Spatial and Functional Genomics, Children's Hospital of Philadelphia, Philadelphia, United States.
Genome-wide association studies (GWAS) have identified hundreds of genetic signals associated with autoimmune disease. The majority of these signals are located in non-coding regions and likely impact -regulatory elements (cRE). Because cRE function is dynamic across cell types and states, profiling the epigenetic status of cRE across physiological processes is necessary to characterize the molecular mechanisms by which autoimmune variants contribute to disease risk.
View Article and Find Full Text PDFImmunother Adv
June 2024
The Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.
CD8+ T cells contribute to immune responses by producing cytokines when their T-cell receptors (TCRs) recognise peptide antigens on major-histocompability-complex class I. However, excessive cytokine production can be harmful. For example, cytokine release syndrome is a common toxicity observed in treatments that activate T cells, including chimeric antigen receptor (CAR)-T-cell therapy.
View Article and Find Full Text PDFFront Immunol
April 2024
Department of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
Introduction: The clinical success of chimeric antigen receptor-modified T cells (CAR-T cells) for hematological malignancies has not been reproduced for solid tumors, partly due to the lack of cancer-type specific antigens. In this work, we used a novel combinatorial approach consisting of a versatile anti-FITC CAR-T effector cells plus an FITC-conjugated neuroblastoma (NB)-targeting linker, an FITC-conjugated monoclonal antibody (Dinutuximab) that recognizes GD2.
Methods: We compared cord blood (CB), and CD45RA-enriched peripheral blood leukapheresis product (45RA) as allogeneic sources of T cells, using peripheral blood (PB) as a control to choose the best condition for anti-FITC CAR-T production.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!